A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

NCT04267237 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Accrual timelines

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Atezolizumab
DRUG: RO7198457

Sponsor

Hoffmann-La Roche